[
  {
    "ts": null,
    "headline": "RMD vs. LMAT: Which Stock Is the Better Value Option?",
    "summary": "RMD vs. LMAT: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=909ae50e48ccb2874cdfe53c0ea1eda826b4c63ea1f1d32aaf8a6e186cfc9a5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732639207,
      "headline": "RMD vs. LMAT: Which Stock Is the Better Value Option?",
      "id": 131653016,
      "image": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "RMD vs. LMAT: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=909ae50e48ccb2874cdfe53c0ea1eda826b4c63ea1f1d32aaf8a6e186cfc9a5c"
    }
  },
  {
    "ts": null,
    "headline": "International Expansion Supports BSX Stock Amid Macroeconomic Woes",
    "summary": "BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.",
    "url": "https://finnhub.io/api/news?id=13bcbcd0f66f7a628b8df163e11cb4566e24d3074dc6e8790c14d9fdded31b1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732632600,
      "headline": "International Expansion Supports BSX Stock Amid Macroeconomic Woes",
      "id": 131652378,
      "image": "https://media.zenfs.com/en/zacks.com/228e67967b066e7a755ae3614be720e1",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.",
      "url": "https://finnhub.io/api/news?id=13bcbcd0f66f7a628b8df163e11cb4566e24d3074dc6e8790c14d9fdded31b1a"
    }
  },
  {
    "ts": null,
    "headline": "ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee",
    "summary": "Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval. The company plans a nationwide launch in the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=d5ba5a2f677ca4e496b8c5ea96c600bcc76cc8b7cd984e4fc65b077b0e5c6cfa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732631460,
      "headline": "ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee",
      "id": 131652379,
      "image": "https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval. The company plans a nationwide launch in the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=d5ba5a2f677ca4e496b8c5ea96c600bcc76cc8b7cd984e4fc65b077b0e5c6cfa"
    }
  },
  {
    "ts": null,
    "headline": "Zacks.com featured highlights include InterDigital, Greenbrier, Leidos, ResMed and Kontoor",
    "summary": "InterDigital, Greenbrier, Leidos, ResMed and Kontoor have been highlighted in this Screen of The Week article.",
    "url": "https://finnhub.io/api/news?id=b015dafa1fa5b370e886ebdb351c0efcb0847d59d40c5cb3f657bad6b5ba8597",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732611420,
      "headline": "Zacks.com featured highlights include InterDigital, Greenbrier, Leidos, ResMed and Kontoor",
      "id": 131636112,
      "image": "https://media.zenfs.com/en/zacks.com/a48dd9848d838c94ffae3239ac2f1072",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "InterDigital, Greenbrier, Leidos, ResMed and Kontoor have been highlighted in this Screen of The Week article.",
      "url": "https://finnhub.io/api/news?id=b015dafa1fa5b370e886ebdb351c0efcb0847d59d40c5cb3f657bad6b5ba8597"
    }
  },
  {
    "ts": null,
    "headline": "Downgrading ResMed Inc. Because It's Doing Well",
    "summary": "ResMed Inc. is downgraded from buy to watchful hold due to valuation concerns, despite strong financial performance and growth potential. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=0b9305b202ac461fc3aaf5558acfb2901722eb3bc88919f57a47a6d92a29d810",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732609514,
      "headline": "Downgrading ResMed Inc. Because It's Doing Well",
      "id": 131632452,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/629586908/image_629586908.jpg?io=getty-c-w1536",
      "related": "RMD",
      "source": "SeekingAlpha",
      "summary": "ResMed Inc. is downgraded from buy to watchful hold due to valuation concerns, despite strong financial performance and growth potential. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=0b9305b202ac461fc3aaf5558acfb2901722eb3bc88919f57a47a6d92a29d810"
    }
  }
]